Pharmaceutical composition capable of reducing hyperlipidemia and losing weight
A technology of composition and hyperlipidemia, applied in the direction of drug combination, pharmaceutical formula, plant raw materials, etc., can solve problems such as adverse reactions, large side effects, and easy rebound
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Publication Date
- 2014-12-03
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1
Abstract
Description
technical field
[0001] The invention relates to the technical field of traditional Chinese medicines, in particular to a pharmaceutical composition capable of reducing hyperlipidemia and reducing weight. Background technique
[0002] Hyperlipidemia is a common and frequently-occurring disease that seriously threatens human health, and is the number one disease that threatens human life. Due to high blood lipids, fat metabolism disorder is caused, which leads to increased blood viscosity, and later cardiovascular and cerebrovascular diseases such as cerebral thrombosis, coronary heart disease, hypertension, and atherosclerosis.
[0003] At present, the treatment of hyperlipidemia at home and abroad is mainly based on western medicine. For example, "clofibrate" drugs have side effects, and long-term use can damage the liver, kidney and blood cells. "Liping Zhi" and other fibrate lipid-lowering drugs Although the effect is good, it is easy to rebound after stopping the drug, a...
Examples
Embodiment Construction
[0027] Below, the technical solution of the present invention will be described in detail through specific examples. In Examples 1-5, the raw materials of a pharmaceutical composition capable of reducing hyperlipidemia and losing weight proposed by the present invention are composed as shown in the following table in parts by weight.
[0028]
[0029] Adopt embodiment 5 to prepare medicament, two to three times a day, each 10g, two weeks is a course of treatment. 100 cases of hyperlipidemia and obesity were selected, 62 cases were markedly effective after 2 courses of treatment, 26 cases were effective, and 12 cases were ineffective. The marked rate is 62%, the effective rate is 88%, and the ineffective rate is 12%.
[0030] The above is only a preferred embodiment of the present invention, but the scope of protection of the present invention is not limited thereto, any person familiar with the technical field within the technical scope disclosed in the present invention, a...